India Glycols LimitedQ1 FY27 Results & Financial Update
India Glycols Limited: Q1 FY27 consolidated results and company financials – revenue ₹2,988.44 Cr, PAT ₹96.83 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
India Glycols price & chart
Market price₹287.45
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore India Glycols Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
India Glycols reported consolidated revenue from operations of INR 2,988.44 crore for the first quarter ended June 30, 2026, alongside a total consolidated income of INR 2,988.82 crore.
Profit before tax (PBT) reached INR 122.88 crore after factoring in a share of net profit from joint ventures amounting to INR 20.60 crore.
Consolidated net profit after tax (PAT) stood at INR 96.83 crore for the quarter, yielding a basic and diluted earnings per share (EPS) of INR 14.45.
Segment contributions illustrated strong top-line contributions from potable spirits and bio-based specialities, balancing input cost movements and operational expenditures across the consolidated group.
Profit after tax was ₹96.83 Cr for the reported quarter. EPS was ₹14.45 for the reported quarter.
01 · Business model
What does India Glycols do?
India Glycols Limited operates a diversified manufacturing footprint spanning bio-based specialities and performance chemicals, potable spirits, ennature biopharma products, and bio-fuels.
The company generates its primary revenue streams through the large-scale processing of green chemicals, industrial solvents, and alcoholic beverages distributed across domestic and international markets.
Its operational model integrates chemical processing facilities with captive green-fuel and specialized extraction units, supported by joint venture participation in specialty chemical ventures.
02 · Historical context
What shaped the business before this quarter
The Board previously approved a composite scheme involving the demerger of the biopharma undertaking into Ennature Bio Pharma Limited and the spirits and biofuel undertaking into IGL Spirits Limited, with an appointed date of April 1, 2026.
Following NCLT meetings held on March 24, 2026, where the scheme was approved by shareholders and creditors, the tribunal reserved its order on July 2, 2026, and subsequently pronounced its decision sanctioning the scheme on July 17, 2026.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹2,988.44 Cr |
| Total income | ₹2,988.82 Cr |
| Profit before tax | ₹122.88 Cr |
| Profit after tax | ₹96.83 Cr |
| EPS | ₹14.45 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 3.2% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 4.1% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.38 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Potable spirits served as the largest revenue engine, contributing INR 2,218.67 crore to consolidated segment revenue.
Bio-based specialities and performance chemicals contributed INR 363.25 crore to top-line revenue during the quarter.
Bio-fuel operations generated INR 323.22 crore, while ennature biopharma added INR 83.30 crore in quarterly revenue.
What drove margins
Excise duty expenses formed the largest cost component at INR 1,858.05 crore, directly influencing gross margin dynamics in the potable spirits segment.
Cost of materials consumed stood at INR 678.45 crore, while power and fuel expenses accounted for INR 115.42 crore of total operating overheads.
Finance costs were contained at INR 25.18 crore, and depreciation and amortisation expenses amounted to INR 42.48 crore for the quarter.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Potable spirits recorded segment results (profit before interest and tax) of INR 75.03 crore on revenue of INR 2,218.67 crore.
Bio-based specialities and performance chemicals delivered segment profit before interest and tax of INR 31.39 crore.
Bio-fuel generated segment results of INR 27.03 crore, and ennature biopharma posted segment results of INR 7.25 crore.
06 · Strategy & new businesses
How the company is trying to change its growth mix
Key operational disclosures for the quarter indicated that India Glycols Limited standalone generated revenue of INR 354.64 crore with EBITDA of INR 40.22 crore, IGL Spirits Limited recorded revenue of INR 2,541.89 crore with EBITDA of INR 120.10 crore, and Ennature Bio Pharma Limited posted revenue of INR 90.39 crore with EBITDA of INR 9.98 crore.
07 · Reported developments
What changed operationally
The company recorded a positive share of net profit from joint ventures (Clariant IGL Specialty Chemicals Private Limited) amounting to INR 20.60 crore.
08 · Beyond the numbers
What changed beyond the numbers
Reported update
Statutory Auditor Review
The financial results for Q1 FY27 received a limited review report with unmodified conclusions from statutory auditors K.N. Gutgutia & Co.
09 · Key Q&A
The quarter, answered directly
What does India Glycols do?
India Glycols Limited operates a diversified manufacturing footprint spanning bio-based specialities and performance chemicals, potable spirits, ennature biopharma products, and bio-fuels.
What is the clearest takeaway from Q1 FY27?
India Glycols reported consolidated revenue from operations of INR 2,988.44 crore for the first quarter ended June 30, 2026, alongside a total consolidated income of INR 2,988.82 crore.
What drove revenue or demand?
Potable spirits served as the largest revenue engine, contributing INR 2,218.67 crore to consolidated segment revenue.
What mattered most for margins or profitability?
Excise duty expenses formed the largest cost component at INR 1,858.05 crore, directly influencing gross margin dynamics in the potable spirits segment.
What changed operationally beyond the headline numbers?
Key operational disclosures for the quarter indicated that India Glycols Limited standalone generated revenue of INR 354.64 crore with EBITDA of INR 40.22 crore, IGL Spirits Limited recorded revenue of INR 2,541.89 crore with EBITDA of INR 120.10 crore, and Ennature Bio Pharma Limited posted revenue of INR 90.39 crore with EBITDA of INR 9.98 crore.
What should the next disclosure help confirm?
Receipt of the certified true copy of the NCLT order pronounced on July 17, 2026, regarding the composite scheme of arrangement.
10 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
11 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Certified NCLT Order: Receipt of the certified true copy of the NCLT order pronounced on July 17, 2026, regarding the composite scheme of arrangement.
- 02
Demerger Execution Milestones: Further exchange and regulatory disclosures regarding the operational segregation of IGL Spirits Limited and Ennature Bio Pharma Limited.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.